Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT01126931
  4. Details
NCT01126931 Clinical Trial

Wormwood in Chronic Progressive Disorders With Reduced Appetite

Cancer Clinical Trial

Official title:
Pilot Trial With Wormwood to Improve Appetite in Cancer, Autoimmune Diseases, Depression and Old Age

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01126931
Other study ID # Appetite and Weight Loss
Secondary ID
Status Recruiting
Phase N/A
First received May 17, 2010
Last updated May 19, 2010
Start date February 2006
Est. completion date December 2012

Study information
Verified date February 2008
Source University Hospital Freiburg
Contact Simone S Krebs, MD, Ph.D
Phone (+49) -761-27-3913
Email simone.krebs@uniklinik-freiburg.de
Is FDA regulated No
Health authority Germany: Federal Ministry of Food, Agriculture and Consumer Protection
Study type Observational

Clinical Trial Summary

Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.

Trial aims at observing beneficial effects of wormwood supplementation in various chronic disorders associated with reduced appetite

Description:

Supplementation with wormwood in chronic disorders associated with reduced appetite.

Examples:

1. Cancer

2. Autoimmune diseases such as Crohns disease and IgA Nephropathy

3. Old age

4. Chronic stress and depression

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date December 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Appetite and weight loss

- Chronic progressive disease

Exclusion Criteria:

- Life expectancy less than 3 months

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Germany University of Freiburg, Medical Faculty Freiburg Baden

Sponsors (1)
Lead Sponsor Collaborator
University Hospital Freiburg

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial. Phytomedicine. 2010 Apr;17(5):305-9. doi: 10.1016/j.phymed.2009.10.013. Epub 2009 Dec 3. — View Citation

Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine. 2007 Feb;14(2-3):87-95. Epub 2007 Jan 19. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Improvement in appetite 6-12 months Yes
Secondary Improvement in quality of life 12-24 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients